Announcements Trials
Browse Landscape Eligibility

Clinical Trials

452 trials
RecentStart dateEnrollment
Taxes × Clear all

Phase

Phase 2 213Phase 1 92Phase 3 63Phase 1/2 54Phase 2/3 10Phase NA 8Phase EARLY_PHASE1 6Phase 4 2

Status

Completed 175Recruiting 73Active not recruiting 69Unknown 49Terminated 43Withdrawn 25Not yet recruiting 14Suspended 2Temporarily not available 1Enrolling by invitation 1

Sponsor Class

OTHER 273NIH 95INDUSTRY 45NETWORK 35UNKNOWN 3OTHER_GOV 1

Study Type

Interventional 448Observational 3Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 136Breast 104Gynecologic 87Thoracic 77Head & Neck 25Genitourinary 17Other solid neoplasm 12Dermatologic 12Tumor-Agnostic 10Sarcoma 9Lymphoid 4Other hematologic neoplasm 3CNS 3Endocrine 2Classical hematology 2Plasma cell 1Other neoplasm 1Other 1Myeloid 1

Conditions

Breast Neoplasms 75Pancreatic Neoplasms 72Carcinoma, Non-Small-Cell Lung 62Fallopian Tube Neoplasms 36Ovarian Neoplasms 35Triple Negative Breast Neoplasms 32Neoplasm Metastasis 23Lung Neoplasms 21Squamous Cell Carcinoma of Head and Neck 18Breast Neoplasms, Male 16Endometrial Neoplasms 15Neoplasms 13Brenner Tumor 13Uterine Cervical Neoplasms 12Stomach Neoplasms 12Carcinoma, Ovarian Epithelial 12Melanoma 11Esophageal Neoplasms 11Adenocarcinoma of Lung 9Unspecified Adult Solid Tumor, Protocol Specific 8Cholangiocarcinoma 8Inflammatory Breast Neoplasms 7Adenocarcinoma Of Esophagus 7Urinary Bladder Neoplasms 6Colorectal Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Recurrence 5Pancreatic Adenocarcinoma 5Oropharyngeal Neoplasms 5Mouth Neoplasms 5

Interventions

Cyclophosphamide 2681Cisplatin 2665Carboplatin 2462Radiotherapy 2370Paclitaxel 2264Gemcitabine 2128pembrolizumab 1993Docetaxel 1883Bevacizumab 1821Fluorouracil 1548Capecitabine 1532Oxaliplatin 1440Dexamethasone 1330Nivolumab 1300Doxorubicin 1260Rituximab 1249Magnetic Resonance Spectroscopy 1150Etoposide 1126Irinotecan 1038Leucovorin 1020Drug Therapy 999Cytarabine 964Pemetrexed 891fludarabine 889Specimen Handling 822Vincristine 793Lenalidomide 791Cetuximab 785Prednisone 785Trastuzumab 785

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT01167712 2026-03-18

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
692 enrolled 11 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms

NCT01386385 2026-03-18

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
53 enrolled 21 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

NCT02135042 2026-03-18

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT02194738 2026-03-18

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

National Cancer Institute (NCI)

Phase NA Active not recruiting
8,300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03907475 2026-03-18

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04092283 2026-03-18

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
660 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04143711 2026-03-18

Study of DF1001 in Patients With Advanced Solid Tumors

Dragonfly Therapeutics

Phase 1/2 Completed
270 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05019716 2026-03-18

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

NCT05256225 2026-03-18

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT05422794 2026-03-18

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
57 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05554341 2026-03-18

Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05554380 2026-03-18

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05564377 2026-03-18

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT05635708 2026-03-18

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

BeOne Medicines

Phase 2 Active not recruiting
400 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05673200 2026-03-18

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05685602 2026-03-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
3,680 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
320 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT07061977 2026-03-18

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
336 enrolled
Gynecologic

Locally Advanced Cervical Adenocarcinoma

NCT07281417 2026-03-18

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
813 enrolled 16 charts 1 FDA
GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT04267848 2026-03-17

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

National Cancer Institute (NCI)

Phase 3 Recruiting
1,210 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06203600 2026-03-17

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT03725436 2026-03-16

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
28 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04083599 2026-03-16

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
350 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05227664 2026-03-16

A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Akeso

Phase 2 Active not recruiting
120 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04001829 2026-03-13

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
249 enrolled 14 charts
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT05285358 2026-03-13

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

City of Hope Medical Center

Phase 1 Recruiting
12 enrolled
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

University of Washington

Phase 2 Recruiting
20 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05689671 2026-03-10

ANTELOPE

Charite University, Berlin, Germany

Phase 4 Active not recruiting
136 enrolled
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT07198074 2026-03-10

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
255 enrolled
Gynecologic

Endometrial Neoplasms

NCT04253964 2026-03-06

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Wake Forest University Health Sciences

Phase 2 Recruiting
105 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01970722 2026-03-05

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

City of Hope Medical Center

Phase 1 Active not recruiting
40 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
579 enrolled 17 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
582 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05721755 2026-03-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Eastern Cooperative Oncology Group

Phase 3 Active not recruiting
290 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
4,994 enrolled 11 charts
Breast

Breast Adenocarcinoma

NCT07444541 2026-03-03

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Anova Innovation Limited

Phase 1/2 Not yet recruiting
84 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04233866 2026-03-02

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
176 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04266249 2026-03-02

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
2,175 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05382559 2026-03-02

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07441681 2026-03-02

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

NRG Oncology

Phase 3 Not yet recruiting
454 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT01345851 2026-02-25

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Jonsson Comprehensive Cancer Center

Phase NA Active not recruiting
29 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT05753306 2026-02-25

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Mayo Clinic

Phase 2 Recruiting
40 enrolled
GastrointestinalOther neoplasm

Gastric Adenocarcinoma

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

NCT06998940 2026-02-20

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

SWOG Cancer Research Network

Phase 3 Recruiting
94 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04892953 2026-02-19

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

M.D. Anderson Cancer Center

Phase 2 Recruiting
51 enrolled
Thoracic

Lung Neoplasms

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
203 enrolled 22 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT02530489 2026-02-17

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
37 enrolled 8 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡